October 28, 2021 5:55pm
Earnings: Alnylam Pharmaceuticals (ALNY) dives -$29.97 or -15.15% to $162.19 after earnings net LPS (loss-per-share) of $204.5 M or -$1.72 per share with $2.23 M in cash as revenue stumbles per release
Pre-open indication results: 6 HITs and 0 MISS
My version of the session’s “indications” is about what you need to know; it’s what did happen after the opening, mid-day and to the close
An objective, fact and numbers-based narrative – check the numbers!
The Dow closed UP +239.79 points (+0.68%); the S&P closed UP +44.74 points (+0.98%) while the Nasdaq closed UP +212.28 points (+1.39%)
Henry’omics:
The stock market reached record levels … came despite a disappointing economic report on Thursday.
Are we to be ready for a goodbye Friday to come back next week?
Note: Biostage (BSTG) was flat $0.00 to $3.10 with 95 shares traded after Wednesday’s move from -$0.40 with 216 shares traded until the “pump” was turned-on with 1,676 shares traded to close +$0.10 – where is the SEC?
Economic Data Docket: GDP growth for the Q3 came in at 2.0%, below the 2.8% expected. The reading marks a slowdown from 6.7% growth in Q2.
- The GDP report showed the economy decelerated to expand at the slowest rate in over one year for the July through September quarter.
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Thursday opened positive at 18/13, 3 flats and 1 acquired, stayed positive at the mid-day at 23/10, 1 flat and 1 acquired, ending with a positive close of 23/9, 2 flats and 1 acquired;
RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: ya’ think sentiment is slipping, let’s, see? After a seven (7) sector stumbles out of eight (8) sessions, the probabilities of some upside are still relative yet, the aftermarket was very slim.” … https://www.regmedinvestors.com/articles/12158
Pre-open indication results: 6 Hit: < Biostage (BSTG $0.00); Maintaining SELL and profit: bluebird bio (BLUE +$0.87), Intellia Therapeutics (NTLA +$6.51), Mesoblast (MESO -$0.05), BioLife Solutions (BLFS +$2.25), Global Blood Therapeutics (GBT +$3.55)> and 0 MISS <
Key Metric - volume:
Sector volume was LOW with 5 of the 23-upside having higher than the 3-month average volume with LOW volume of 3 of 9-downside having higher than the 3-month average volume;
Downside volume leaders:
- Alnylam Pharmaceuticals (ALNY) -$28.97 with 2.766 m shares traded,
- Athersys (ATHX) -$0.02 with 2.512 m shares traded,
- Solid Biosciences (SLDB) -$3.00 with 2.31 m shares traded.
Upside volume leaders:
- Adverum Biotechnologies (ADVM) +$0.22 with 3 m shares traded,
- Global Blood Therapeutics (GBT) +$3.55 with 1.932 m shares traded,
- Homology Medicine (FIXX) +$0.11 with 1.254 m shares traded.
There are clear winners and losers
Jumping with share pricing momentum (10 of 10):
- Intellia Therapeutics (NTLA +$6.51 after Wednesday’s -$2.40, Tuesday’s -$1.55 and Monday’s +$1.97),
- Global Blood Therapeutics (GBT +$3.55 after Wednesday’s +$2.79, Tuesday’s -$0.86 and Monday’s -$0.71),
- Ultragenyx (RARE +$3.12 after Wednesday’s +$1.15, Tuesday’s +$0.81 and Monday’s +$1.47),
- BioLife Solutions (BLFS +$2.25 after Wednesday’s +$1.23, Tuesday’s +$1.99 and Monday’s +$2.28),
- uniQure NV (QURE +$1.59 after Wednesday’s +$0.68, Tuesday’s -$0.98 and Monday’s +$0.90),
- Ionis Pharmaceuticals (IONS -$1.39),
- Editas Medicine (EDIT +$1.35 after Wednesday’s -$1.10, Tuesday’s -$0.31 and Monday’s +$0.39),
- Regenxbio (RGNX +$1.31 after Wednesday’s -$0.76, Tuesday’s -$0.57 and Monday’s +$0.41),
- CRISPR Therapeutics (CRSP +$1.22 after Wednesday’s -$2.28, Tuesday’s -$1.64 and Monday’s +$1.14),
- Fate Therapeutics (FATE +$1.14 after Wednesday’s -$4.47, Tuesday’s +$1.15 and Monday’s -$0.84),
Hammered in today’s market (9 of 9):
- Alnylam Pharmaceuticals (ALNY -$28.97 after Wednesday’s -$6.55, Tuesday’s -$1.96 and Monday’s +$1.06),
- ReNeuron (RENE.L -$3.00 after Wednesday’s -$2.50, Tuesday’s +$4.00 and Monday’s +$1.50)
- Solid Biosciences (SLDB -$3.00),
- Pluristem (PSTI -$0.07),
- Brainstorm Cell Therapeutics (BCLI -$0.06),
- Voyager therapeutics (VYGR -$0.05 after Wednesday’s +$0.02),
- Mesoblast (MESO -$0.05),
- Athersys (ATHX -$0.02),
- Chinook Therapeutics (KDNY -$0.01 after Wednesday’s +$0.04, Tuesday’s +$0.03 and Monday’s -$0.21),
Closing Flat:
- 2 – Caladrius Biosciences (CLBS), Biostage (BSTG) and 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Thursday, the IBB closed up +1.68% and XBI closed up +3.23
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Thursday was down -0.45 points or -2.65% at 16.53
October, the first month of Q3/21:
Thursday closed positive with 23 advancers, 9 decliners, 2 flats and 1 acquired
Wednesday closed negative with 10 advancers, 23 decliners, 1 flat and 1 acquired
Tuesday closed negative with 9 advancers, 24 decliners, 1 flat and 1 acquired
Monday (10/25) closed negative with 15 advancers, 17 decliners, 2 flat and 1 acquired
The BOTTOM LINE: The sector closed with more than a few highs while many just regained altitude.
Alnylam Pharmaceuticals (ALNY) cut to the heart of its share price after its net loss and news pre-the open.
We are seeing a to date, a one <uniQure (QURE)> earnings release that initiated Q3 earnings reporting season beginning the start of the tug-of-war between share pricing that is softer than usual which LPS (loss-per-share) is proving to be less than estimates and expectations.
The Nasdaq set record closing highs taking the stem, cell and gene therapy sector along with it – finally!
What I wrote yesterday, still is relevant … “Don't let earnings week take advantage of you. Be ready to act on up-coming earnings news, good or bad, but don't be too hasty.”
I say take ANY profit if one can … to have “powder” after the pricing “drops” …
We'll be seeing the results these couples of weeks as Alnylam Pharmaceuticals (ALNY) on 10/28 followed by Intellia Therapeutics (NTLA) on 11/4, followed by Sage Therapeutics (SAGE) and Ultragenyx Pharmaceuticals (RARE) on 11/2, Fate therapeutics (FATE) on 11/4, Vericel (VCEL on 11/9 and Athersys (ATHX) on 11/15 – so far.
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
